{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:43:35Z","timestamp":1783100615111,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732540"],"award-info":[{"award-number":["2023M732540"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01056-0","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T07:01:45Z","timestamp":1713942105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-5281","authenticated-orcid":false,"given":"Yue","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4505-9439","authenticated-orcid":false,"given":"Xuefeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118:4041\u201352.","journal-title":"Blood"},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl J Med. 2020;382:1811\u201322.","journal-title":"N. Engl J Med"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128:60\u201371.","journal-title":"Blood"},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:614704.","journal-title":"Front Immunol"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6:e630\u2013e7.","journal-title":"Lancet Haematol"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood.2020007930","volume":"138","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Lakes N, Tran M, Castillo N, Jordan MB. JAK inhibition for murine HLH requires complete blockade of IFN-gamma signaling and is limited by toxicity of JAK2 inhibition. Blood. 2021;138:1034\u20139.","journal-title":"Blood"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","volume":"151","author":"JA Joly","year":"2023","unstructured":"Joly JA, Vallee A, Bourdin B, Bourbonnais S, Patey N, Gaboury L, et al. Combined IFN-gamma and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. J Allergy Clin Immunol. 2023;151:247\u201359 e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"1137037","DOI":"10.3389\/fimmu.2023.1137037","volume":"14","author":"S Albeituni","year":"2023","unstructured":"Albeituni S, Oak N, Tillman HS, Stroh A, Keenan C, Bloom M, et al. Cellular and transcriptional impacts of Janus kinase and\/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1137037.","journal-title":"Front Immunol"},{"key":"1056_CR10","doi-asserted-by":"crossref","unstructured":"Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, et al. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105:e210\u2013e212.","DOI":"10.3324\/haematol.2019.222471"},{"key":"1056_CR11","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.jaci.2018.10.068","volume":"143","author":"S Humblet-Baron","year":"2019","unstructured":"Humblet-Baron S, Franckaert D, Dooley J, Ailal F, Bousfiha A, Deswarte C, et al. IFN-gamma and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2019;143:2215\u201326 e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1056_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/art.41076","volume":"72","author":"TN Burn","year":"2020","unstructured":"Burn TN, Weaver L, Rood JE, Chu N, Bodansky A, Kreiger PA, et al. Genetic deficiency of interferon-gamma reveals interferon-gamma-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:335\u201347.","journal-title":"Arthritis Rheumatol"},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.4049\/jimmunol.1501035","volume":"196","author":"E Brisse","year":"2016","unstructured":"Brisse E, Imbrechts M, Put K, Avau A, Mitera T, Berghmans N, et al. Mouse cytomegalovirus infection in BALB\/c mice resembles virus-associated secondary hemophagocytic lymphohistiocytosis and shows a pathogenesis distinct from primary hemophagocytic lymphohistiocytosis. J Immunol. 2016;196:3124\u201334.","journal-title":"J Immunol"},{"key":"1056_CR14","doi-asserted-by":"publisher","first-page":"e28886","DOI":"10.1002\/pbc.28886","volume":"68","author":"S Ehl","year":"2021","unstructured":"Ehl S, von Bahr Greenwood T, Bergsten E, Fischer A, Henter JI, Hines M, et al. Is neutralization of IFN-gamma sufficient to control inflammation in HLH? Pediatr Blood Cancer. 2021;68:e28886.","journal-title":"Pediatr Blood Cancer"},{"key":"1056_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.it.2008.07.002","volume":"29","author":"H Kelchtermans","year":"2008","unstructured":"Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol. 2008;29:479\u201386.","journal-title":"Trends Immunol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01056-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T07:02:58Z","timestamp":1713942178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01056-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01056-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee at The First Affiliated Hospital of Soochow University. We have obtained consent to publish from the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors critically reviewed the report and approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"70"}}